A variant human alpha-7 acetylcholine receptor subunit, and methods of production and use thereof
CA 2275180 A1 · Owner: Abbott Laboratories · Inventors: Roch, Jean-Marc; Touma, Edward; Briggs, Clark A.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A variant human .alpha.7 nicotinic acetylcholine receptor (nAChR) polypeptide is provided wherein the variant contains an amino acid substitution at the valine-274 position of the wild-type human .alpha.7 nAChR. Nucleic acid molecules encoding the variant human .alpha.7 nAChR vectors and host cells , containing such nucleic acid molecules are also provided. In addition methods , are provided for producing the variant as are methods of using such variants for screening compounds for activity at the nAChR.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed December 22, 1997. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended December 22, 2017.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by December 22, 2019.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.